[go: up one dir, main page]

MX2009011362A - Uso de temperatura baja y/o ph bajo en el cultivo celular. - Google Patents

Uso de temperatura baja y/o ph bajo en el cultivo celular.

Info

Publication number
MX2009011362A
MX2009011362A MX2009011362A MX2009011362A MX2009011362A MX 2009011362 A MX2009011362 A MX 2009011362A MX 2009011362 A MX2009011362 A MX 2009011362A MX 2009011362 A MX2009011362 A MX 2009011362A MX 2009011362 A MX2009011362 A MX 2009011362A
Authority
MX
Mexico
Prior art keywords
cell culture
low
low temperature
present
reduced
Prior art date
Application number
MX2009011362A
Other languages
English (en)
Inventor
Jose Manuel Gomes
Gregory Walter Hiller
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39493848&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009011362(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2009011362A publication Critical patent/MX2009011362A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee un nuevo método para reducir el mal plegamiento y agregación de proteínas en el cultivo celular, mediante el desarrollo del cultivo celular a una temperatura reducida y/o a pH reducido. Como resultado, la calidad de la proteína producida en el cultivo celular mejora enormemente. Por lo tanto, la presente invención facilita las mejoras en la eficacia de proteínas terapéuticas producidas en el cultivo celular.
MX2009011362A 2007-04-23 2008-04-22 Uso de temperatura baja y/o ph bajo en el cultivo celular. MX2009011362A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91338207P 2007-04-23 2007-04-23
PCT/US2008/061123 WO2008131374A1 (en) 2007-04-23 2008-04-22 Use of low temperature and/or low ph in cell culture

Publications (1)

Publication Number Publication Date
MX2009011362A true MX2009011362A (es) 2009-11-05

Family

ID=39493848

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009011362A MX2009011362A (es) 2007-04-23 2008-04-22 Uso de temperatura baja y/o ph bajo en el cultivo celular.
MX2009011363A MX2009011363A (es) 2007-04-23 2008-04-22 Metodo de produccion de proteinas utilizando compuestos anti-senectud.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009011363A MX2009011363A (es) 2007-04-23 2008-04-22 Metodo de produccion de proteinas utilizando compuestos anti-senectud.

Country Status (26)

Country Link
US (2) US9988662B2 (es)
EP (2) EP2139986B1 (es)
JP (3) JP2010524504A (es)
KR (3) KR20140132016A (es)
CN (3) CN105039473A (es)
AR (2) AR066238A1 (es)
AU (2) AU2008242632B2 (es)
BR (2) BRPI0810511A2 (es)
CA (2) CA2685552C (es)
CL (2) CL2008001159A1 (es)
CO (2) CO6241165A2 (es)
DK (2) DK2139987T5 (es)
ES (2) ES2646090T3 (es)
HK (1) HK1216261A1 (es)
HU (1) HUE034776T2 (es)
IL (2) IL201719A (es)
MX (2) MX2009011362A (es)
PA (2) PA8777701A1 (es)
PE (2) PE20090731A1 (es)
PL (2) PL2139986T3 (es)
PT (2) PT2139986T (es)
RU (2) RU2478702C2 (es)
SI (2) SI2139986T1 (es)
TW (2) TW200902708A (es)
WO (2) WO2008131375A1 (es)
ZA (1) ZA200907426B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2500413A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
KR20090127326A (ko) 2007-03-02 2009-12-10 와이어쓰 폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도
EP3327132A3 (en) * 2007-08-09 2018-07-18 Wyeth LLC Use of perfusion to enhance production of fed-batch cell culture in bioreactors
WO2010034015A2 (en) 2008-09-22 2010-03-25 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
KR20110091678A (ko) * 2008-10-20 2011-08-12 아보트 러보러터리즈 단백질 ａ 친화성 크로마토그래피를 이용한 항체의 분리 및 정제
NZ592097A (en) 2008-10-20 2013-01-25 Abbott Lab Viral inactivation during purification of il-12 and il-18 antibodies
RU2012127383A (ru) * 2009-12-02 2014-01-10 Акселерон Фарма Инк. Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке
EP3862423A1 (en) 2010-04-26 2021-08-11 Novartis AG Improved cell cultivation process
US20130295613A1 (en) 2010-12-28 2013-11-07 Chugai Seiyaku Kabushiki Kaisha Animal cell culturing method
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3712252A1 (en) 2013-03-15 2020-09-23 F. Hoffmann-La Roche AG Cell culture compositions with antioxidants and methods for polypeptide production
SG11201507875RA (en) * 2013-03-26 2015-10-29 Coherus Biosciences Inc Protein production method
US9416181B2 (en) 2013-05-06 2016-08-16 Abbvie Inc. Compositions for cell culture and methods of using the same
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
USD759075S1 (en) * 2014-04-11 2016-06-14 Nutonian, Inc. Display screen with graphical user interface
USD759076S1 (en) * 2014-04-18 2016-06-14 Nutonian, Inc. Display screen with graphical user interface
TWI743024B (zh) 2014-06-06 2021-10-21 美商健臻公司 灌注培養方法及其用途
JP6948942B2 (ja) * 2014-10-15 2021-10-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド タンパク質産物の等電性プロファイルをシフトさせる方法およびその使用
AR104050A1 (es) * 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
WO2017065559A1 (ko) * 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
CN107460221B (zh) * 2016-06-02 2021-01-15 正大天晴药业集团股份有限公司 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法
JP7213180B2 (ja) 2016-10-19 2023-01-26 エフ．ホフマン－ラ ロシュ アーゲー 免疫コンジュゲートを製造するための方法
KR102701102B1 (ko) * 2017-02-17 2024-08-29 론자 리미티드 생물학적 생성물 변이체의 생산 방법
KR20240149973A (ko) * 2017-10-16 2024-10-15 리제너론 파마슈티칼스 인코포레이티드 세포 배양에서 공정 변수를 제어하기 위한 원위치 라만 분광법 시스템 및 방법
AU2018361430B2 (en) 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
US20220364034A1 (en) * 2018-11-02 2022-11-17 WuXi Biologics Ireland Limited Cell culture process by intensified perfusion with continuous harvest and without cell bleeding
US20230035363A1 (en) * 2019-03-04 2023-02-02 Amgen Inc. In vivo reversibility of high molecular weight species
TW202140075A (zh) 2020-01-09 2021-11-01 美商梅爾莎納醫療公司 具有含肽之連接子的位置特異性抗體－藥物共軛體
WO2022254319A1 (en) * 2021-06-01 2022-12-08 Pfizer Inc. Cell culture method for producing sfgfr3 polypeptide
KR102682066B1 (ko) * 2021-10-12 2024-07-05 프레스티지바이오로직스 주식회사 항체 집단의 제조 방법
JPWO2024135853A1 (es) * 2022-12-23 2024-06-27
CN120752329A (zh) * 2023-02-03 2025-10-03 安进公司 细胞培养方法
CN118166053B (zh) * 2024-03-15 2025-02-07 通化安睿特生物制药股份有限公司 一种制备低o-糖基化水平的重组人白蛋白的方法
CN118006716B (zh) * 2024-03-15 2024-09-10 通化安睿特生物制药股份有限公司 制备高表达且低o-糖基化水平的重组人白蛋白的方法
TWI891362B (zh) * 2024-05-10 2025-07-21 國立臺灣大學 鴨蛋白水解物及其製備方法及增強肌肉耐力與抗疲勞用途
WO2025248500A1 (en) 2024-05-31 2025-12-04 Janssen Biotech, Inc. Antibody drug conjugates that target enpp3

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
DE10399023I2 (de) * 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5610033A (en) 1990-04-25 1997-03-11 Novo Nordisk A/S Method of producing proteins with FVIII activity and/or FVIII derivatives
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
EP0571390B1 (en) * 1990-11-23 2000-03-08 Peptech Limited The delay, prevention and/or reversal of cell senescence
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
SG47030A1 (en) 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
US5516964A (en) * 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5830761A (en) * 1995-06-07 1998-11-03 Genetics Institute, Inc. Medium and methods for culturing mammalian cho cells
CA2229043C (en) * 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
DE69738539T2 (de) * 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
CA2318376A1 (en) 1998-01-12 1999-07-15 Betagene, Inc. Compositions and methods for regulated secretion from neuroendocrine cell lines
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
MXPA01011047A (es) 1999-04-30 2003-10-14 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.
JP3090657B1 (ja) 1999-08-09 2000-09-25 伸子 蓮山 ゼオライト製造方法およびゼオライト製造装置
EP1103615A1 (en) 1999-11-25 2001-05-30 Universite De Geneve Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
AUPR038200A0 (en) * 2000-09-26 2000-10-19 Beta Peptide Foundation Pty Ltd, The Compositions and methods for delaying, preventing, rejuvenating or reversing senescence
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US6544076B2 (en) 2001-07-10 2003-04-08 Alan L. Pocrass Dual function RJ connector
IL161358A0 (en) * 2001-11-19 2004-09-27 Novo Nordisk As Process for preparing insulin compounds
CA2417689C (en) 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
WO2003083066A2 (en) * 2002-03-27 2003-10-09 Immunex Corporation Methods for increasing polypeptide production
GB0208041D0 (en) 2002-04-08 2002-05-22 Lonza Biologics Plc Method of culturing animal cells
PT2287288E (pt) 2002-07-09 2012-12-10 Baxter Int Meio isento de proteína animal para cultura de células
PL376381A1 (en) 2002-07-15 2005-12-27 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
BR0317723A (pt) 2002-12-23 2005-11-22 Bristol Myers Squibb Co Processo de cultura de células de mamìfero para a produção de proteìna
JP2007525176A (ja) 2003-04-25 2007-09-06 イミュネックス・コーポレーション 組換えタンパク質発現の誘導剤
CN1565631A (zh) * 2003-06-27 2005-01-19 上海中信国健药业有限公司 肿瘤坏死因子受体－免疫球蛋白的融合蛋白用于急性肺损伤药物的用途
AU2004286938B2 (en) 2003-10-27 2011-06-30 Wyeth Removal of high molecular weight aggregates using hydroxyapatite chromatography
WO2005064013A1 (en) 2003-12-23 2005-07-14 Bart Janssen The use of carnosine metabolism-associated genes to determine genetic predisposition/susceptibility to diabetic nephropathy
EP2156852B1 (en) * 2004-07-07 2011-04-13 Coloplast A/S Catheter comprising ESTANE 58212.
BRPI0510674A (pt) 2004-07-15 2007-12-26 Xencor Inc variantes fc otimizadas
US7700318B2 (en) 2004-08-25 2010-04-20 Amprotein Corporation Chimeric polypeptide and use thereof
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US7294484B2 (en) * 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US7426440B2 (en) * 2004-09-24 2008-09-16 Nutritional Bioscience Ltd. Repair and protection factor scoring method for bioactive agents
US20070102622A1 (en) 2005-07-01 2007-05-10 Olsen Richard I Apparatus for multiple camera devices and method of operating same
WO2007011595A2 (en) 2005-07-15 2007-01-25 Neuren Pharmaceuticals Limited Neural regeneration peptides and antioxidants protect neurons from degeneration
DE102005034616B4 (de) * 2005-07-18 2008-07-03 Elringklinger Ag Brennstoffzelleneinheit und Brennstoffzellenstapel
PE20070796A1 (es) * 2005-10-24 2007-08-15 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
DK2041270T3 (da) * 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
KR20090127326A (ko) 2007-03-02 2009-12-10 와이어쓰 폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도
EP3327132A3 (en) 2007-08-09 2018-07-18 Wyeth LLC Use of perfusion to enhance production of fed-batch cell culture in bioreactors
JP7587678B2 (ja) 2021-09-15 2024-11-20 香港時代新能源科技有限公司 電池セル、電池、電力消費装置、電池セルの製造方法及び設備

Also Published As

Publication number Publication date
ES2424217T9 (es) 2014-01-27
AU2008242633A1 (en) 2008-10-30
EP2139986A1 (en) 2010-01-06
WO2008131374A1 (en) 2008-10-30
JP5557736B2 (ja) 2014-07-23
IL201719A (en) 2015-09-24
CN101668845B (zh) 2015-11-25
RU2009139054A (ru) 2011-05-27
US9988662B2 (en) 2018-06-05
CL2008001156A1 (es) 2009-01-16
US20080274507A1 (en) 2008-11-06
CO6241166A2 (es) 2011-01-20
AR066239A1 (es) 2009-08-05
PA8777701A1 (es) 2008-11-19
SI2139987T1 (sl) 2013-09-30
KR101560421B1 (ko) 2015-10-15
KR20100017211A (ko) 2010-02-16
DK2139986T3 (en) 2017-10-02
ES2424217T3 (es) 2013-09-30
DK2139987T5 (da) 2014-01-27
KR20100016271A (ko) 2010-02-12
CN101679943A (zh) 2010-03-24
HK1216261A1 (zh) 2016-10-28
JP2010524503A (ja) 2010-07-22
PT2139986T (pt) 2017-11-14
JP5881755B2 (ja) 2016-03-09
EP2139987A1 (en) 2010-01-06
IL201719A0 (en) 2011-08-01
TW200902709A (en) 2009-01-16
PE20090153A1 (es) 2009-04-23
KR101540124B1 (ko) 2015-07-28
CA2685552C (en) 2016-02-23
PA8778001A1 (es) 2008-11-19
CL2008001159A1 (es) 2008-11-03
RU2009138226A (ru) 2011-05-27
CO6241165A2 (es) 2011-01-20
PT2139987E (pt) 2013-08-22
PE20090731A1 (es) 2009-07-15
EP2139987B9 (en) 2013-11-13
HK1142095A1 (zh) 2010-11-26
CN105039473A (zh) 2015-11-11
ES2646090T3 (es) 2017-12-12
MX2009011363A (es) 2009-11-05
RU2478702C2 (ru) 2013-04-10
AR066238A1 (es) 2009-08-05
EP2139986B1 (en) 2017-09-06
DK2139987T3 (da) 2013-09-02
IL201720A (en) 2016-03-31
IL201720A0 (en) 2011-08-01
BRPI0810482A2 (pt) 2014-10-07
CA2684727A1 (en) 2008-10-30
SI2139986T1 (sl) 2017-11-30
BRPI0810511A2 (pt) 2014-10-07
WO2008131375A1 (en) 2008-10-30
PL2139986T3 (pl) 2018-01-31
KR20140132016A (ko) 2014-11-14
JP2014113161A (ja) 2014-06-26
HUE034776T2 (en) 2018-02-28
PL2139987T3 (pl) 2013-11-29
AU2008242632B2 (en) 2013-11-28
US20080269132A1 (en) 2008-10-30
CA2685552A1 (en) 2008-10-30
EP2139987B1 (en) 2013-07-03
AU2008242632A1 (en) 2008-10-30
TW200902708A (en) 2009-01-16
CA2684727C (en) 2018-09-04
US12054762B2 (en) 2024-08-06
ZA200907426B (en) 2010-08-25
AU2008242633B2 (en) 2014-09-18
JP2010524504A (ja) 2010-07-22
CN101668845A (zh) 2010-03-10

Similar Documents

Publication Publication Date Title
MX2009011362A (es) Uso de temperatura baja y/o ph bajo en el cultivo celular.
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
MY161866A (en) Cell culture improvements
WO2008154014A3 (en) A method for culturing mammalian cells to improve recombinant protein production
BR122019022434B8 (pt) método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular
SG196784A1 (en) Stem cell cultures
WO2008013943A3 (en) High-cell density fed-batch fermentation process for producing recombinant protein
CA3005308C (en) Media and fermentation methods for producing polysaccharides in bacterial cell culture
MX2010000348A (es) Cultivo de celulas madre pluripotentes individuales.
WO2007098150A3 (en) Photobioreactor and uses therefor
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
ATE531383T1 (de) Therapeutische verwendung eines wachstumsfaktors, metrnl
MX2009008175A (es) Metodos para producir vacunas basadas en levadura.
UA102236C2 (uk) Похідні еритропоетин-міметичного пептиду та їх фармацевтичні солі, їх одержання і застосування
WO2005028626A3 (en) Cell culture media
UA92157C2 (ru) Способ продуцирования гормона роста
EA201490945A1 (ru) Набор, содержащий заменитель сыворотки и лабильные факторы
EA201492185A1 (ru) Способ получения рекомбинантной идуронат-2-сульфатазы
NO20080580L (no) Serumfritt kulturmedium for produksjon av redkombinante gonadotropiner
WO2011123811A3 (en) Production of post-translationally hydroxylated recombinant proteins in bacteria
MX2013002144A (es) Alimentacion alcalina.
EA201170025A1 (ru) Способы повышения жизнеспособности и продукции культуры клеток
EA200900984A1 (ru) Улучшение клеточного роста
TW200738752A (en) Modulation of MDL-1 activity for treatment of inflammatory disease
MX2014012407A (es) Metodo para incrementar la secrecion de proteinas recombinantes.

Legal Events

Date Code Title Description
FG Grant or registration